According to a recent LinkedIn post from Forge Biologics, the company recently hosted Scientific and Medical Advisory Board member Maritza McIntyre, Ph.D., for an internal discussion on regulatory and industry experience. The conversation, as summarized in the post, emphasized the role that industry participants and CDMOs can have in providing practical, development-stage insights to inform regulatory thinking.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that sharing what is technically and operationally feasible across gene therapy programs may help align innovation with evolving regulatory expectations. For investors, this emphasis on collaborative engagement with regulators could indicate a strategic focus on de-risking development pathways and potentially shortening time to market for gene therapy clients.
The LinkedIn post also notes that Forge Biologics has invested in advancing the field through novel technologies and close collaboration with regulators and partners. This positioning may strengthen the company’s value proposition as a CDMO in the gene therapy space, potentially supporting contract wins, long-term client relationships, and competitive differentiation in a highly specialized market.